1. CCLHD Research Repositories

Cecily Forsyth

View Statistics Email Alert RSS Feed

Profile

Loading... 2 0 20 0 false
Credit Name
Cecily Forsyth
Full Name
Forsyth, Cecily
Variants
Forsyth, Cecily J
 
Main Affilation
Central Coast Local Health District
 
Department
 
ORCID
Loading... 3 0 20 0 false

Publications

Refined By:
Type:  Journal Article
Date Issued:  [2010 TO 2019]

Results 1-28 of 28 (Search time: 0.001 seconds).

PreviewIssue DateTitleAuthor(s)
1Sep-2019Outpatient rituximab, ifosfamide, etoposide (R-IE) in patients older than 60 years with relapsed or refractory diffuse large B-cell lymphoma who are not candidates for stem cell transplantationForsyth, Cecily J ; Joshi, M.; Taper, J.; Rowlings, P.; Campbell, P.; Crispin, P.; Harvey, M.; Underhill, C.; Bayley, A.; Byth, K.; Huang, G.; Hertzberg, M.
2Apr-2019The natural history of vascular and other complications in patients treated with nilotinib for chronic myeloid leukemiaForsyth, Cecily J ; Minson, A.G.; Cummins, K.; Fox, L.; Costello, B.; Yeung, D.; Cleary, R.; Tatarczuch, M.; Burbury, K.; Motorna, O.; Shortt, J.; Fleming, S.; McQuillan, A.; Schwarer, A.; Harrup, R.; Holmes, A.; Ratnasingam, S.; Chan, K.L.; Hsu, W.H.; Ashraf, A.; Putt, F.; Grigg, A.
3Apr-2019Changing incidence of myeloproliferative neoplasms in Australia, 2003-2014Forsyth, Cecily J ; Baade, P.D.; Ross, D.M.; Anderson, L.A.; Fritschi, L.
4Jan-2019Hereditary haemorrhagic telangiectasiaForsyth, Cecily J ; Mangkorntongsakul, Varitsara 
5Dec-2018The delayed diagnosis of myeloproliferative neoplasms is common and results in a high incidence of potentially preventable thrombotic complicationsForsyth, Cecily J ; Melville, K.; Tiley, Campbell 
6Nov-2018Recommendations for the use of pegylated interferon-alpha in the treatment of classical myeloproliferative neoplasmsForsyth, Cecily J ; Chan, Wai-Hoong ; Grigg, A.; Cook, N.C.; Lane, S.W.; Burbury, K.; Perkins, A.C.; Ross, D.M.
7Aug-2018Hydroxycarbamide Plus Aspirin Versus Aspirin Alone in Patients With Essential Thrombocythemia Age 40 to 59 Years Without High-Risk FeaturesForsyth, Cecily J ; Godfrey, A.L.; Campbell, P.J.; MacLean, C.; Buck, G.; Cook, J.; Temple, J.; Wilkins, B.S.; Wheatley, K.; Nangalia, J.; Grinfeld, J.; McMullin, M.F.; Kiladjian, J.J.; Green, A.R.; Harrison, C.N.
8Apr-2018Humoral immune failure defined by immunoglobulin class and immunoglobulin G subclass deficiency is associated with shorter treatment-free and overall survival in Chronic Lymphocytic LeukaemiaForsyth, Cecily J ; Crassini, K.R.; Zhang, E.; Balendran, S.; Freeman, J.A.; Best, O.G.; Mackinlay, N.J.; Han, P.; Stevenson, W.S.; Mulligan, S.P.
9Jan-2018Delayed-onset heparin-induced thrombocytopenia complicated by arterial and venous thrombosesForsyth, Cecily J ; Harrison; Balendran, S.; Harrison, A.; Morel-Kopp, M. C.; Ward, C.
10May-2017The incidence and natural history of dasatinib complications in the treatment of chronic myeloid leukemiaForsyth, Cecily J ; Fox, L.; Cummins, K.D.; Costello, B.; Yeung, D.; Cleary, R.; Tatarczuch, M.; Burbury, K.; Motorna, O.; Shortt, J.; Fleming, S.; McQuillan, A.; Schwarer, A.; Harrup, R.; Holmes, A.; Ratnasingam, S.; Chan, K.L.; Hsu, W.H.; Ashraf, A.; Putt, F.; Grigg, A.
11May-2017Raccoon eyes in systemic light chain amyloidosisForsyth, Cecily J ; Tiley, Campbell 
12May-2017Upfront lower dose lenalidomide is less toxic and does not compromise efficacy for vulnerable patients with relapsed refractory multiple myeloma: final analysis of the phase II RevLite studyForsyth, Cecily J ; Quach, H.; Fernyhough, L.; Henderson, R.; Corbett, G.; Baker, B.; Browett, P.; Blacklock, H.; Underhill, C.; Cannell, P.; Trotman, J.; Neylon, A.; Harrison, S.; Link, E.; Swern, A.; Cowan, L.; Dimopoulos, M.A.; Miles Prince, H.
13Mar-2017A case-based discussion of clinical problems in the management of patients treated with ruxolitinib for myelofibrosisForsyth, Cecily J ; Ho, P.J.; Bajel, A.; Burbury, K.; Dunlop, L.; Durrant, S.; Perkins, A.C.; Ross, D.M.
14Feb-2017Clinicopathological differences exist between CALR- and JAK2-mutated myeloproliferative neoplasms despite a similar molecular landscape: data from targeted next-generation sequencing in the diagnostic laboratory.Forsyth, Cecily J ; Agarwal, R.; Blombery, P.; McBean, M.; Jones, K.; Fellowes, A.; Doig, K.; Westerman, D.A.
15Jan-2017Busulfan is effective second-line therapy for older patients with Philadelphia-negative myeloproliferative neoplasms intolerant of or unresponsive to hydroxyureaForsyth, Cecily J ; Douglas, G.; Harrison, C.N.; Bennett, M.; Stevenson, W.S.; Hounsell, J.; Ratnasingam, S.; Ritchie, D.; Ross, D.M.; Grigg, A.
16Aug-2016Correlation of blood counts with vascular complications in essential thrombocythemia: analysis of the prospective PT1 cohortForsyth, Cecily J ; Campbell, P.J.; MacLean, C.; Beer, P.A.; Buck, G.; Wheatley, K.; Kiladjian, J.J.; Harrison, C.N.; Green, A.R.
17Apr-2016Dysregulation of the intrinsic apoptotic pathway mediates megakaryocytic hyperplasia in myeloproliferative neoplasmsForsyth, Cecily J ; Malherbe, J.A.; Fuller, K.A.; Mirzai, B.; Kavanagh, S.; So, C.C.; Ip, H.W.; Guo, B.B.; Howman, R.; Erber, W.N.
18Oct-2015The novel Hsp-90 inhibitor SNX7081 is significantly more potent than 17-AAG against primary CLL cells and a range of haematological cell lines, irrespective of lesions in the TP53 pathwayForsyth, Cecily J ; Best, O.G.; Singh, N.; Mulligan, S.P.
19Feb-2015The oral iron chelator deferasirox inhibits NF-kappaB mediated gene expression without impacting on proximal activation: implications for myelodysplasia and aplastic anaemiaForsyth, Cecily J ; Banerjee, A.; Mifsud, N. A.; Bird, R.; Szer, J.; Tam, C.; Kellner, S.; Grigg, A.; Motum, P.; Bentley, M.; Opat, S.; Grigoriadis, G.
20Feb-2015TIDEL-II: first-line use of imatinib in CML with early switch to nilotinib for failure to achieve time-dependent molecular targets.Yeung, D.; Osborn, M.; White, D.; Branford, S.; Braley, J.; Herschtal, A.; Kornhauser, M.; Issa, S.; Hiwase, D.; Hertzberg, M.; Schwarer, A.; Filshie, R.; Arthur, C.; Kwan, Y.L.; Trotman, J.; Forsyth, Cecily J ; Taper, J.; Ross, D.M.; Beresford, J.; Tam, C.; Mills, A.K.; Grigg, A.; Hughes, T.
21Jul-2014Perioperative and peripartum prevention of venous thromboembolism in patients with hereditary antithrombin deficiency using recombinant antithrombin therapyForsyth, Cecily J ; Paidas, M.J.; Quere, I.; Rodger, M.
22May-2014Cyclical thrombocytosis, acquired von Willebrand syndrome and aggressive non-melanoma skin cancers are common in patients with Philadelphia-negative myeloproliferative neoplasms treated with hydroxyureaForsyth, Cecily J ; Verner, E.; Grigg, A.
23Aug-2013A multicenter, open-label, noncomparative screening study of Enzastaurin in adult patients with Non-Hodgkin LymphomasForsyth, Cecily J ; Gomez-Almaguer, D.; Camargo, J.F.C.; Eliadis, P.E.; Crespo-Solis, E.; Pereira, J.; Gutierrez-Aguirre, C.H.; Rivaz-Vera, S.; Roberson, S.; Lin, B.; Smith, N.V.; Hamid, O.
24Jan-2013Immunoglobulin G subclass deficiency and infection risk in 150 patients with chronic lymphocytic leukemiaForsyth, Cecily J ; Freeman, J.A.; Crassini, K.R.; Best, O.G.; Mackinlay, N.J.; Han, P.; Stevenson, W.S.; Mulligan, S.P.
25Jul-2012The Hsp90 inhibitor SNX-7081 synergizes with and restores sensitivity to fludarabine in chronic lymphocytic leukemia cells with lesions in the TP53 pathway: a potential treatment strategy for fludarabine refractory diseaseForsyth, Cecily J ; Best, O.G.; Che, Y; Singh, N.; Christopherson, R.I.; Mulligan, S.P.
26Apr-2012When should iron chelation therapy be considered in patients with myelodysplasia and other bone marrow failure syndromes with iron overload?Forsyth, Cecily J ; Bird, R.; Kenealy, M.; Wellwood, J.; Leahy, M.F.; Seymour, J.F.; To, L.B.
27Feb-2012Distinguishing types 1 and 2M von Willebrand diseaseForsyth, Cecily J ; Favaloro, E.J.; Koutts, J.
28Aug-2011Positron emission tomography-computed tomography (PET-CT) after induction therapy is highly predictive of patient outcome in follicular lymphoma: analysis of PET-CT in a subset of PRIMA trial participantsForsyth, Cecily J ; Trotman, J.; Fournier, M; Lamy, T.; Seymour, J.F.; Sonet, A.; Janikova, A.; Shpilberg, O.; Gyan, E.; Tilly, H.; Estell, J.; Decaudin, D.; Fabiani, B.; Gabarre, J.; Salles, B.; Van Den Neste, E.; Canioni, D.; Garin, E.; Fulham, M.; Vander Borght, T.; Salles, G.